A Quebec City-based pharmacy chain began removing energy drinks from its store shelves on May 7 to protect young people [1, 2].

The move highlights growing concerns over the accessibility of high-caffeine beverages to minors and the potential for adverse health effects. By removing these products from a healthcare-oriented environment, the chain is taking a preventative stance against caffeine-related complications in youth.

Stores affiliated with Familiprix implemented the removal across Quebec City and other locations in Atlantic Canada [1, 3]. The decision stems from the health risks associated with the high concentrations of caffeine found in many energy drinks [1, 2].

While the specific caffeine levels of the pulled products were not detailed in the local reports, some energy drinks on the global market have been found to contain nine times as much caffeine as a can of Coca-Cola [4]. Such concentrations can lead to heart palpitations, anxiety, and sleep disturbances, particularly in children and adolescents whose bodies are more sensitive to stimulants.

The pharmacy chain focused its efforts on mitigating these risks for young consumers [1, 2]. This action aligns with broader public health discussions regarding the regulation of stimulant-heavy beverages sold in retail environments that also provide medical services.

Reports from the region indicate the removal was a targeted effort to prioritize youth wellness over the sale of these beverages [1, 2]. The chain has not said if the ban is permanent or if specific low-caffeine alternatives will be introduced to replace the removed stock.

“A Quebec City-based pharmacy chain began removing energy drinks from its store shelves on May 7.”

This decision reflects a shifting boundary between retail convenience and public health responsibility. By removing energy drinks, a healthcare-affiliated chain is signaling that the potential for harm to minors outweighs the commercial benefit of selling these products. It may set a precedent for other pharmacy-led retailers in Canada to evaluate the appropriateness of selling high-stimulant beverages in a clinical or health-focused setting.